gip/glp-1 receptor agonist drugs Frontiers GLP-1 Receptor Agonists | New
Description
I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance)
Metseras pipeline includes MET-097i, a GLP-1 receptor agonist designed for once-monthly dosing, and MET-233i, an amylin analog being developed for monthly administration
New analyses involving more than 100,000 patients suggest that users of popular diabetes and weight-loss medications face a lower risk of developing certain cancers and a reduced risk of metastasis.
Purpose of Review The development of long-acting incretin receptor agonists represents a significant advance in the fight against the concurrent epidemics of type 2 diabetes mellitus (T2DM) and obesity
Ozempic alternatives in the GLP-1 family offer effective weight loss pathways
The GLP-1 receptor assay is a powerful tool for the identification of GLP-1 receptor agonists aimed at treating obesity and type 2 diabetes
